Drug
Bgb Dxp593
Bgb Dxp593: highest development phase Phase 1, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGB DXP593 NCT04532294 | Phase 1 | Covid19 |
Latest
No recent events.
Follow Bgb Dxp593 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.